RxDoctor Payments Data

Tiffany Harkleroad, NP

Family · Waycross, GANPI 1174172142

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $13,708 of the $16,304 with a category attached, or 84.1%. It is spread thinly across 60 manufacturers, the largest accounting for just 7.3% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,304in general payments, 2019–2025

Across 554 payments — averaging $29.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1K
  • Pharmacosmos Therapeutics Inc.$1K
  • AstraZeneca$1K
  • Pfizer$944
  • Seagen Inc.$838
  • Johnson & Johnson$820
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$8005%
  • Food & beverage$13,70884%
  • Education$1,79711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck42$1,194
Pharmacosmos Therapeutics Inc.16$1,106
AstraZeneca(2 entities)42$1,012
Pfizer30$944
Seagen Inc.19$838
Johnson & Johnson26$820
Novartis48$791
E.r. Squibb & Sons, L.L.C.26$676
Gilead(2 entities)14$608
Astellas Pharma US Inc17$587
GSK13$473
AbbVie14$464
Daiichi Sankyo Inc.17$432
Takeda Pharmaceuticals U.S.A., Inc.8$409
Sobi, Inc12$382
Bristol Myers Squibb15$377
Genentech, Inc.3$358
Incyte Corporation8$276
Amgen16$259
ADC Therapeutics America, Inc.6$230
Tempus AI, Inc6$219
Sanofi10$208
Novocure Inc.5$196
G1 Therapeutics, Inc.7$196
Lilly USA, LLC7$193
Exelixis Inc.10$188
Adaptive Biotechnologies Corporation4$171
Paratek Pharmaceuticals, Inc.3$166
Eisai Inc.8$164
Genentech USA, Inc.9$157
Jazz Pharmaceuticals Inc.2$153
Octapharma USA, Inc.6$137
Rigel Pharmaceuticals, Inc.3$130
Bayer2$112
Taiho Oncology, Inc.6$110
Boehringer Ingelheim5$110
Alkermes, Inc.1$100
Servier Pharmaceuticals LLC6$100
Immunocore Limited4$92
Sumitomo Pharma America, Inc.4$89
Regeneron Healthcare Solutions, Inc.5$85
Pharmaessentia USA Corporation4$78
Beone Medicines USA, Inc.3$73
Tersera Therapeutics LLC3$69
Pharmacyclics LLC, An Abbvie Company2$65
Morphosys, US Inc.4$64
Myovant Sciences Inc.3$62
Fennec Pharmaceuticals, Inc.4$62
Deciphera Pharmaceuticals Inc.3$61
Puma Biotechnology, Inc.3$59
Array Biopharma Inc4$56
Mirati Therapeutics, Inc.2$46
Karyopharm Therapeutics Inc.1$45
EUSA Pharma (US) LLC2$39
EMD Serono, Inc.1$31
Geron Corporation2$29
Recordati_rare_diseases_inc.1$28
Coherus Oncology, Inc.1$26
Foundation Medicine, Inc.1$21
Beigene USA, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,304 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$5,951
Medicare patients
51
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TasignaNilotinib Hcl12$244,380
EliquisApixaban45$35,292
XareltoRivaroxaban26$18,228
Enoxaparin Sodium12$6,057
Hydroxyurea28$977
Letrozole64$921
Anastrozole36$559
Venlafaxine Hcl ErVenlafaxine Hcl12$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisTasigna$791$244,38012 claims
PfizerEliquis$944$35,29245 claims
Johnson & JohnsonXarelto$820$18,22826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Waycross

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →